{ "meta": { "data_length": 1, "message": "Statements retrieved successfully", "request_url": "http://api.moalmanac.org/statements?agent_id=agent%3Aorg%3Afda&proposition_id=prop%3Avtxr%3A460", "status": "success", "status_code": 200, "timestamp_elapsed": 0.004144, "timestamp_received": "2026-09-25T01:16:38.620187+00:00Z", "timestamp_returned": "2026-09-25T01:16:38.624331+00:00Z", "trace_id": "67d9be69-0d4a-4617-8b4a-d4d819e26ba2" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://dev.moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:fda:afinitor:2:0", "type": "Statement", "description": "The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.", "contributions": [ { "id": "ctrb:vanallenlab:2025-01-10:0", "type": "Contribution", "description": "Additional FDA approvals for initial version", "date": "2025-01-10", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2016-01-29:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2016-01-29", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } }, { "id": "ctrb:fda:2010-10-29:0", "type": "Contribution", "description": "Indication received accelerated approval.", "date": "2010-10-29", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:afinitor", "type": "Document", "documentType": "Regulatory approval", "name": "Afinitor (everolimus) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Afinitor", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "everolimus", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 22334, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2022-02-01", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:460", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C3696", "conceptType": "Disease", "name": "Subependymal Giant Cell Astrocytoma", "mappings": [ { "relation": "broadMatch", "coding": { "id": "coding:oncotree:ENCG", "code": "ENCG", "name": "Encapsulated Glioma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Encapsulated+Glioma+%28ENCG%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C3696", "code": "C3696", "name": "Subependymal Giant Cell Astrocytoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3696" ] } }, "objectTherapeutic": { "id": "tx:ncit:C48387", "conceptType": "Therapy", "name": "Everolimus", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:141704", "code": "141704", "name": "everolimus", "system": "RxNorm", "systemVersion": "20250602", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=141704" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:4324761", "code": "4324761", "name": "Everolimus", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/4324761" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:sctid:428698007", "code": "428698007", "name": "Everolimus", "system": "SNOMED", "systemVersion": "2026-03-01", "iris": [ "https://browser.ihtsdotools.org/?perspective=full&conceptId1=428698007&edition=MAIN/2026-03-01&release=&languages=en" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:19011440", "code": "19011440", "name": "everolimus", "system": "OMOP", "systemVersion": "v20250827", "iris": [ "https://athena.ohdsi.org/search-terms/terms/19011440" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "PI3K/AKT/mTOR inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C48387", "code": "C48387", "name": "Everolimus", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:158", "present": true, "subject": { "id": "bmkr:158", "type": "CategoricalVariant", "name": "TSC1 oncogenic variants", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.o0qRqlKBKx4X0_JQslgG31SX69ml6liV", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_000359.1, the protein product of the MANE Select coding transcript for TSC1 (refseq:NM_000368.5).", "digest": "o0qRqlKBKx4X0_JQslgG31SX69ml6liV", "sequenceReference": { "id": "ga4gh:SQ.a1L5tWilMgJeKiIWlg_QAnVAgy2wvJsp", "type": "SequenceReference", "name": "NP_000359.1", "aliases": [ "ensembl:ENSP00000298552.3", "ga4gh:SQ.a1L5tWilMgJeKiIWlg_QAnVAgy2wvJsp", "refseq:NP_000359.1" ], "description": "The protein product of the MANE Select coding transcript for TSC1 (refseq:NM_000368.5), corresponding to the Refseq protein accession NP_000359.1.", "moleculeType": "protein", "refgetAccession": "SQ.a1L5tWilMgJeKiIWlg_QAnVAgy2wvJsp", "residueAlphabet": "aa" }, "start": 0, "end": 1164, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:12362", "conceptType": "Gene", "name": "TSC1", "primaryCoding": { "id": "coding:hgnc:12362", "code": "HGNC:12362", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12362" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000165699", "code": "ENSG00000165699", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000165699" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:7248", "code": "7248", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/7248" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_000368.5", "code": "NM_000368.5", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_000368.5" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Somatic variant" }, { "name": "chromosome", "value": "9" }, { "name": "start_position", "value": null }, { "name": "end_position", "value": null }, { "name": "reference_allele", "value": null }, { "name": "alternate_allele", "value": null }, { "name": "cdna_change", "value": null }, { "name": "protein_change", "value": null }, { "name": "variant_annotation", "value": null }, { "name": "exon", "value": null }, { "name": "rsid", "value": null }, { "name": "hgvsg", "value": null }, { "name": "hgvsc", "value": null }, { "name": "requires_oncogenic", "value": true } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "25.01d", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:fda:afinitor:2", "type": "Indication", "description": "AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.", "contributions": [ { "id": "ctrb:vanallenlab:2025-01-10:0", "type": "Contribution", "description": "Additional FDA approvals for initial version", "date": "2025-01-10", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } }, { "id": "ctrb:fda:2016-01-29:0", "type": "Contribution", "description": "Indication received traditional approval.", "date": "2016-01-29", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } }, { "id": "ctrb:fda:2010-10-29:0", "type": "Contribution", "description": "Indication received accelerated approval.", "date": "2010-10-29", "contributor": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." } } ], "reportedIn": [ { "id": "doc:fda:afinitor", "type": "Document", "documentType": "Regulatory approval", "name": "Afinitor (everolimus) [package insert]. FDA.", "title": null, "aliases": [], "description": "Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.", "urls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf", "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:fda", "type": "Agent", "agentType": "organization", "name": "Food and Drug Administration", "description": "Regulatory agency that approves drugs for use in the United States." }, "description": "The organization that published this document." }, { "name": "company", "value": "Novartis Pharmaceuticals Corporation.", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": "Afinitor", "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": "everolimus", "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": null, "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": 22334, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2022-02-01", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }